PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1)

This study systematically elucidates the multi-component, multi-target, and multi-pathway mechanisms underlying Epimedium's anti-ovarian cancer effects, thereby providing a theoretical foundation for its potential clinical application. It should be noted, however, that these findings are computational predictions and thus require experimental validation.

This study provides novel insights into the genetic blueprint of bGBM. Further research with larger cohorts is needed to validate these findings and better understand the molecular features of bGBM.

Pathway analysis revealed predominant WNT/β-catenin signaling in EBTs versus RAS-MEK-ERK pathway alterations in SMBTs resembling the seromucinous variant of ovarian endometrioid carcinoma, with additional involvement of PI3K-PTEN-AKT-mTOR and SWI/SNF chromatin remodeling pathways in both. These findings demonstrate that EBTs and SMBTs possess distinct morphologic and molecular profiles, expanding the molecular characterization of early ovarian endometrioid-type neoplasms.

The presence of CDK4, CCND2, PDGFRA, PIK3R1, MYCN, and EGFR alterations result in an intermediate patient survival in IDH-mutant astrocytoma. Adding these molecular alterations should be considered in future diagnostic classification systems to improve stratification of high-risk patients.

These findings reveal the therapeutic potential of TN against AML through inhibiting the PI3K/AKT axis. With no PI3K/AKT inhibitors targeting AML approved as first-line therapies, TN emerges as a promising candidate for AML treatment, offering a safer natural alternative.

This study demonstrates that A. Radix inhibits tumor cell proliferation through multi-component targeting of the PI3K-Akt signaling pathway, providing new therapeutic targets and theoretical evidence for CRC treatment. Furthermore, it establishes a methodological framework for the modern investigation of traditional Chinese medicine formulations.

This case illustrates the characteristic clinicopathological and molecular features of CMMRD-associated pediatric high-grade glioma and underscores the critical role of routine mismatch repair immunohistochemistry. Integrated histological and genomic evaluation is essential for accurate diagnosis, appropriate genetic counseling, and potential therapeutic implications. Key Points • This case represents a pediatric high-grade glioma arising in the setting of PMS2-related constitutional mismatch repair deficiency (CMMRD). • The tumor exhibited an ultra-hypermutated profile with co-occurring TP53, PIK3CA, PIK3R1, and PTEN mutations. • Loss of PMS2 expression in both tumor and non-neoplastic cells was critical in establishing the diagnosis of CMMRD. • The presence of a developmental venous anomaly may relate to underlying PIK3R1 pathway alterations. • Routine mismatch repair immunohistochemistry is essential in pediatric high-grade gliomas, even in the absence of a family history.

Using our approach, the following phytochemicals, with predicted moderate bioavailability, high GI absorption, and probable binding with insulin resistance targets, are recommended for further in vivo or in vitro validation for insulin resistance activity: boldione (a steroid); aurantiamide acetate and aurantiamide (peptide derivatives); O-ethyl-[(3,4-dihydroxyphenyl)methyl] carbamothioate and O-methyl-N-[(4-hydroxyphenyl)methyl] carbamothioate (thiocarbamates); 4α,6α-dihydroxyeudesman-8β,12-olide (a sesquiterpenoid); sanleng acid and tianshic acid (fatty acid derivatives); 2',5,5',7-tetrahydroxyflavone; 2',3,5,7-tetrahydroxyflavone; and 6-hydroxykaempferol (flavonoids). By combining network centrality measures of targets, using ROC-derived thresholds for docking energies, and considering ubiquity of phytochemicals, our refined network pharmacology approach may aid in discovering key bioactive phytochemicals as potential chemical markers for standardization and differentiation of an herbal drug.

TOP2A, PABPN1, BCL2L12, TRIM14, PIK3R1 and LAPTM4B were novel PCD-related prognostic markers for PRAD. BCL2L12 might take part in the resistance of 6-AA in PRAD via the cysteine-type endopeptidase activity pathway.

Notably, all hub genes demonstrated strong diagnostic performance, highlighting their potential as sensitive biomarkers of glyphosate exposure. Collectively, this study provides comprehensive insights into gene expression changes associated with glyphosate exposure in hepatoma cells, linking them to hepatic metabolic dysregulation and immune modulation and suggesting a panel of hub genes with potential diagnostic and therapeutic significance.

In a castrated PC-3 xenograft model, PLP (400 mg/kg/day) suppressed tumor volume growth by 91.7% and tumor weight growth by 78.0% compared with the control group, showing efficacy comparable to abiraterone/prednisone without hepatorenal toxicity...Integrative transcriptomic and multi-omics analyses revealed coordinated downregulation of phosphatidylinositol 3-kinase-protein kinase B-mechanistic target of rapamycin signaling and upregulation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). Functional validation showed that overexpression of phosphoinositide-3-kinase regulatory subunit 1 rescued PLP-induced tumor suppression, whereas knockdown of PGC-1α abolished its antioxidative and antiproliferative effects, indicating that both pathways are critically involved. These findings suggest that PLP combats CRPC by simultaneously inhibiting oncogenic signaling and mitigating oxidative stress, positioning it as a promising natural therapeutic candidate for CRPC.

P=N/A, N=14, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting | Trial completion date: May 2029 --> Dec 2029 | Trial primary completion date: Sep 2028 --> Jun 2029